NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions

No Longer AvailableN/A

Sponsor: Hoffmann-La Roche

Conditions: Cancers With NTRK, ROS1, or ALK Gene Fusions

Interventions: Entrectinib

Countries: United States

Expanded access to entrectinib will be given to patients with cancers harboring NTRK1/2/3, ROS1, or ALK gene fusions who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for entrectinib.

Eligibility overview

Sex: ALL

Study type: EXPANDED_ACCESS

Eligibility criteria

Inclusion Criteria:

* Diagnosis of advanced cancer with an NTRK1, NTRK2, NTRK3, ROS1, or ALK gene fusion
* Unable to participate in an ongoing entrectinib (RXDX-101) clinical trial
* Willing and able to provide written, signed informed consent
* Medically suitable for treatment with entrectinib (RXDX-101)

Exclusion Criteria:

* Currently enrolled in an ongoing clinical study with any other investigational agent

Locations (1)

San Diego, California, United States